` CTSO (Cytosorbents Corp) vs S&P 500 Comparison - Alpha Spread

CTSO
vs
S&P 500

Over the past 12 months, CTSO has underperformed S&P 500, delivering a return of -1% compared to the S&P 500's +16% growth.

Stocks Performance
CTSO vs S&P 500

Loading
CTSO
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CTSO vs S&P 500

Loading
CTSO
S&P 500
Difference
www.alphaspread.com

Performance By Year
CTSO vs S&P 500

Loading
CTSO
S&P 500
Add Stock

Competitors Performance
Cytosorbents Corp vs Peers

Cytosorbents Corp
Glance View

Market Cap
62.5m USD
Industry
Health Care

CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Monmouth Junction, New Jersey and currently employs 221 full-time employees. The company went IPO on 2005-06-17. The firm is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The firm's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The firm's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.

CTSO Intrinsic Value
0.97 USD
Overvaluation 3%
Intrinsic Value
Price
Back to Top